End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.97 CNY | -0.43% | +1.75% | +16.75% |
Mar. 29 | Beijing Tong Ren Tang Chinese Medicine CEO Steps Down; Acting CEO Appointed | MT |
Mar. 22 | Bank of Shanghai Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 4.65 and 4.26 for the ongoing fiscal year and 2024 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.75% | 13.67B | B- | ||
+17.28% | 212B | C+ | ||
+3.46% | 74.29B | A- | ||
+10.09% | 55.41B | C+ | ||
-1.30% | 45.88B | B- | ||
+11.93% | 46.55B | B- | ||
+18.21% | 45.51B | B | ||
+9.96% | 36.84B | B- | ||
-15.91% | 35.27B | A- | ||
-96.60% | 32.24B | - | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 601229 Stock
- Ratings Bank of Shanghai Co., Ltd.